IP Library Granted Patent US 9,439,977
Granted Patent B2
US 9,439,977 · App. 12/706,625 · Granted Sep 13, 2016

Methods and compositions for treatment of interferon-resistant tumors

Inventor: William F. Benedict (The Woodlands, TX)
Assignee: FKD Therapies Oy
A61K48/0008A61K9/0034A61K9/1271A61K38/212A61K48/00C07K14/56C12N15/86C12N2710/10343
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,439,977
App. No.
12/706,625
Granted
Sep 13, 2016
Kind
B2
Abstract

The present invention provides a method for the treatment of interferon resistant tumors through the use of recombinant vectors encoding interferon species. In particular it is noted that interferon species provided by recombinant vectors possesses properties not associated with the recombinantly produced interferon proteins. The present invention further provides compositions useful in the treatment of interferon resistant tumors using recombinant vectors encoding interferons.

Claims (13)

1. A method of treating an interferon-resistant lung cancer by contacting said cancer with a recombinant vector encoding an interferon.

2. The method of claim 1 wherein said recombinant vector is an adenovirus.

3. The method of claim 2 wherein said adenovirus is replication deficient.

4. The method of claim 3 wherein said interferon is an interferon α.

5. The method of claim 4 wherein said interferon alpha is selected from the group consisting of interferon α2b, interferon α2a, and interferon α2α1.

6. The method of claim 1 wherein cells of said interferon-resistant lung cancer have been exposed to an enhancing agent.

7. The method of claim 6 where in the enhancing agent is Syn3.

8. The method of claim 7 wherein said vector and sand enhancing agent are administered together.

9. The method of claim 7 wherein said interferon is interferon α2b.

10. The method of claim 7 wherein said vector and sand enhancing agent are administered contemporaneously.

11. The method of claim 7 wherein said vector is administered within an hour after administering the enhancing agent.

12. The method of claim 7 wherein said vector and said enhancing agent are administered by inhalation.

13. The method of claim 7 wherein said vector and said enhancing agent are administered intralesionally.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2013
From: BENEDICT, WILLIAM F.
To: CANJI, INC.
Reel/Frame 030401/0515 →
Continuity (3)
Continuation 11009689 · Dec 10, 2004
Provisional Application 60528525 · Dec 10, 2003
Related Publication 20100266547A1 · Oct 21, 2010